No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 1.2x · 10th percentile · as of Sep 8, 2026
Annual revenue · last 4 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current calculation evidence unavailable. Quote observation: unavailable. Latest historical point 2026-09-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Medline Inc. (MDLN) stock was $34.05 as of Sep 9, 2026, 4:00 PM EDT, up 0.00% from the previous close.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers.
Medical - Instruments & Supplies · Northfield, IL
Next Earnings Date
Nov 4, 2026
55 days away
EPS Estimate
0.34
Revenue Est.
$7.72B
Last Quarter Results
EPS
$0.50
vs Estimate
$0.32
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MDLN | $28.79B | $34.05 | +0.00% | N/A | N/A | N/A | N/A |
| 2GEHC | $29.44B | $65.17 | -2.41% | -17.05% | N/A | N/A | vs MDLN |
| 3WAT | $30.28B | $404.81 | +0.00% | +30.26% | -1.05% | +9.71% | vs MDLN |
| 4ZTS | $30.74B | $73.31 | +0.00% | -50.62% | -17.96% | +4.56% | vs MDLN |
| 5BIIB | $31.14B | $210.73 | -0.83% | +46.79% | -6.83% | -3.34% | vs MDLN |
| 6LH | $26.33B | $321.10 | +0.00% | +18.39% | +5.37% | +11.11% | vs MDLN |
2.58
$7.68B
vs Estimate
$7.52B
Consensus Rating
Based on 25 analysts
Average Price Target
$44.60
+31.0% upside
Low
$34.00
Current
$34.05
High
$55.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.33 | $0.35 | $0.36 | 14 |
| Quarter ending Dec 2026 | $0.39 | $0.41 | $0.44 | 13 |
| Quarter ending Mar 2027 | $0.34 | $0.35 | $0.35 | 5 |
| Quarter ending Jun 2027 | $0.38 | $0.38 | $0.39 | 5 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.35 | $1.49 | $1.55 | 12 |
| FY 2027 | $1.48 | $1.57 | $1.67 | 15 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $7.69B | $7.72B | $7.73B | 14 |
| Quarter ending Dec 2026 | $8.38B | $8.48B | $8.53B | 14 |
| Quarter ending Mar 2027 | $7.76B | $7.85B | $7.94B | 9 |
| Quarter ending Jun 2027 | $8.20B | $8.29B | $8.39B | 7 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $31.15B | $31.23B | $31.28B | 18 |
| FY 2027 | $33.46B | $33.67B | $33.78B | 18 |
